Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.

GLP-1 receptor agonists represent an emerging therapeutic approach in stroke prevention, addressing a critical gap in cardiovascular risk management. This narrative review examines the mechanisms by which GLP-1 agonists may reduce stroke incidence through multiple pathways, including improved glycemic control, weight reduction, and enhanced vascular function. The authors synthesize current evidence regarding the efficacy and safety profile of these agents in high-risk populations. As stroke remains a leading cause of morbidity and mortality globally, identifying novel preventive strategies is essential. This review highlights the promising potential of GLP-1 receptor agonists as adjunctive therapy and discusses implications for clinical practice and future research directions in cerebrovascular disease prevention.

Recent comprehensive analysis of over 90,000 patients across eleven clinical trials reveals that GLP-1 medications reduce the risk of major cardiovascular events by approximately thirteen percent over nearly three years. These drugs, widely recognized for facilitating weight loss, demonstrate substantial cardioprotective benefits extending beyond blood sugar and weight management. The study, published in Cardiovascular Diabetology–Endocrinology Reports, examined long-term outcomes in high-risk populations including individuals with type 2 diabetes, obesity, and existing heart conditions. GLP-1 receptor agonists appear to protect cardiovascular health through multiple mechanisms, including inflammation reduction, improved blood vessel function, and mitigation of key risk factors. This represents the most comprehensive review to date of long-term cardiovascular outcomes associated with these medications when used for prolonged periods exceeding one year.

A University of Virginia-led study presented at Heart Rhythm 2026 reveals that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce atrial fibrillation risk independently of weight loss. The retrospective analysis examined 13,034 patients who initiated GLP-1 RA therapy between 2020 and 2024, compared against a propensity score-matched control group of over 385,000 individuals never receiving the medication. Results demonstrated that GLP-1 RA users experienced significantly better survival rates and substantially lower atrial fibrillation risk, with benefits persisting regardless of weight change. These findings suggest GLP-1 RAs offer direct cardiovascular rhythm benefits beyond their established weight reduction effects, potentially providing important therapeutic advantages for patients at risk of atrial fibrillation.

Recent research demonstrates that GLP-1 receptor agonists, widely prescribed for diabetes and obesity management, provide significant cardiovascular protection in high-risk patient populations. A comprehensive systematic review and meta-analysis examined the long-term safety and efficacy of these medications in individuals with established cardiovascular disease risk factors. The findings reveal that GLP-1 therapies substantially reduce major cardiovascular events, offering promising new therapeutic benefits beyond their original glycemic control applications. While these drugs were initially developed to manage type 2 diabetes, large-scale clinical trials have confirmed their protective effects in vulnerable populations. However, further investigation is needed to understand their potential benefits in broader populations without pre-existing high cardiovascular risk, highlighting opportunities for expanded clinical applications and improved patient outcomes.

This systematic review and meta-analysis synthesizes data from randomized, placebo-controlled cardiovascular outcome trials to evaluate the long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in high-risk cardiovascular populations. GLP-1 receptor agonists are increasingly prescribed for type 2 diabetes and obesity management, yet their sustained cardiovascular effects in vulnerable patients require comprehensive assessment. The study systematically examined trials published between January 2015 and May 2025, focusing on studies with at least 3,000 participants and minimum twelve-month follow-up periods. The primary endpoint assessed was major adverse cardiovascular events, with additional secondary outcomes evaluated. This research provides critical evidence regarding both the metabolic and direct cardiovascular benefits of this important drug class in high-risk populations.

We’ve all heard that making simple lifestyle changes today can help prevent heart disease down the line. But what if you already have key risk factors for heart disease, or even a diagnosis of heart disease itself? Is it too late to turn the tide by turning over a new behavioral leaf?Not according to Fatmata Jalloh, NP-C, a cardiology nurse practitioner with the USC Cardiac and Vascular Institute, part of Keck Medicine of USC. “And don’t take my word for it,” she says. “Studies have proven that lifestyle changes improve your risk factors so you can stop moving along that spectrum to cardiovascular disease.”

GLP-1 receptor agonists — sold under brand names like Ozempic and Mounjaro — were initially developed to treat diabetes. But instead of addressing biomarkers linked to certain disease outcomes, these drugs influence the central cardio-kidney metabolic process, Vaduganathan said. This overarching approach has made GLP-1 drugs the most effective and tolerable choice for most patients treating diabetes and obesity. It’s also what makes it likely that they influence a number of closely related diseases.

Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.

The results show that patients with type 1 diabetes have more than twice the risk of stent complications compared to patients without diabetes. For patients with type 2 diabetes, the risk is also elevated, but not as significantly. Complications include both narrowing of the artery in the stent and blood clots in the stent.

La plupart des cibles des médicaments anti-obésité sont situées au niveau du système nerveux central, en particulier au niveau de l’hypothalamus, région clé de la régulation de la prise alimentaire et du signal de satiété. Leur intérêt est évident tant les bénéfices des mesures hygiéno-diététiques sont difficiles à obtenir, à maintenir dans le temps et insuffisants pour modifier drastiquement la trajectoire des personnes présentant une obésité sévère (IMC > 40 kg/m2)(2).

Despite promising results from existing randomized controlled trials of semaglutide and tirzepatide in those with obesity-related HFpEF, regulatory authorities and professional societies have not approved or endorsed the use of these drugs for HFpEF, due in part to the studies’ relatively small sample sizes and unknown generalizability. The researchers therefore used data from three large U.S. insurance claims databases to emulate two previous, placebo-controlled trials of semaglutide and tirzepatide in new study populations that were an average of 19 times larger than those previously evaluated.

Patients with type 2 diabetes initiated with metformin monotherapy had longer survival than did matched, non-diabetic controls. Those treated with sulphonylurea had markedly reduced survival compared with both matched controls and those receiving metformin monotherapy. This supports the position of metformin as first-line therapy and implies that metformin may confer benefit in non-diabetes. Sulphonylurea remains a concern.

Growth factors are important for wound healing because they regulate key cellular functions. However, in diabetic wounds, these growth factors are rapidly broken down by other enzymes known as proteases. This dramatically slows down wound recovery. At the same time, diabetic wounds are characterised by persistently high levels of inflammation. We wanted to tackle these two issues by using microneedles for both delivery and extraction. It is minimally invasive, can be fabricated with precision, and allows for the active compounds to be painlessly administered directly into wounds. Microneedle patches are excellent materials for wound healing.

Companies like Dexcom and Insulet have been working to expand the reach of their devices from Type 1 diabetes into Type 2, which would include millions of people in the U.S.

Over about 3.5 years, Al-Aly and his colleagues tracked more than 200,000 people with diabetes on GLP-1 drugs and about 1.7 million people with diabetes using other blood-sugar-lowering medications. They tracked the effects of GLP-1 drugs on 175 health conditions. Compared with other diabetes medications, GLP-1 drugs were linked to a lower risk of dozens of conditions, including heart disease, stroke and kidney disease. They also lowered the risk of psychotic disorders by 18%, Alzheimer’s disease by 12%, and addiction disorders by an average of 13%.

An observational study of patients with type 2 diabetes treated for coronary artery disease with second-generation drug-eluting stents (DESs) has found a significant association between poor glycaemic control and a higher risk of stent failure driven by in-stent restenosis.

I can explain that I prescribed a glucagon-like peptide 1 (GLP-1) receptor agonist because the patient had diabetes and was overweight, and multiple studies show that this class of drug leads to weight loss and reduced mortality risk. But then I get the follow-up: Sure, but why THAT GLP-1 drug? Why did you pick semaglutide (Ozempic) over tirzepatide (Mounjaro)? Here's where I run out of good answers. Sometimes I choose a drug because that's what the patient's insurance has on their formulary. Sometimes it's because it's cheaper in general. Sometimes, it's just force of habit. I know the correct dose, I have experience with the side effects — it's comfortable.

In June, the FDA released a warning about the new antiobesity medications, stating it had received reports of adverse events after people self-administered semaglutide from a compounding pharmacy. The warning also states that compounding pharmacies may be selling salt forms of the active ingredient, including semaglutide sodium and semaglutide acetate, though the FDA is not aware of any basis for compounding a drug using semaglutide salts that would meet federal requirements.

Health experts urge women not to use Ozempic or similar drugs to increase fertility, due to increased risks of birth defects and miscarriage.